| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_42e94091a4fc81b8d0237117707cc7ee |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-497 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 |
| filingDate |
2006-10-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c847419ad3f9c5a661a4d912efa7ac3d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b3c27a973bc09c7ca67d9b46f8c92ae6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_55287ce31c1ec24cd173cf8e43a9ce04 |
| publicationDate |
2007-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2007093499-A1 |
| titleOfInvention |
Use of dasatinib for the treatment of bone metastasis |
| abstract |
The present disclosure is directed to a method of treating bone metastasis, hypercalcemia, and/or bone resorption comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) n nor pharmaceutically acceptable salt, hydrate or solvate thereof. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010226853-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8222256-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009045535-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009232828-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009045535-A2 |
| priorityDate |
2005-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |